Abstract
Objective: Despite advances, overall prognosis for advanced epithelial ovarian cancer (EOC) remains poor. Considering elevated TGFβ expression correlates with poor prognosis in ovarian cancer, this study aims to determine whether a maintenance vigil could provide improvement in relapse-free survival. Vigil is an autologous tumor cell vaccine constructed from autologous harvested tumor tissue transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin, thereby creating TGFβ expression control.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
